Figure 8. RTrx1 attenuates GVHD and preserves GVL activity.

BDF1 mice were lethally irradiated and underwent transplantation with 5 × 10⁶ per mouse TCD-BM with or without purified T cells (3 × 10⁶ per mouse) from B6 mice. One group of recipients was injected with RTrx1 at 5 μg/mouse/day from day –1 to day 14. Recipient mice were also infused with luciferase-transduced p815 cells (5000 cells per mouse) at the day of BMT. (A and B) Recipients were monitored for clinical scores and post-BMT survival. (C) Tumor growth was monitored using BLI on the dates indicated. Data shown here are from 2 combined experiments (n = 10). The BLI (C) is from 1 representative experiment. For comparison of recipient survival among groups, the log-rank test was used to determine statistical significance. Clinical scores were compared using a nonparametric Mann-Whitney U test. *P < 0.05 and ***P < 0.001.